Roberta M Moretti
Overview
Explore the profile of Roberta M Moretti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
467
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Moretti R, Montagnani Marelli M, Taylor D, Martini P, Marzagalli M, Limonta P
PLoS One
. 2014 Apr;
9(4):e93713.
PMID: 24722580
Gonadotropin-releasing hormone (GnRH) receptors are expressed in prostate cancer, specifically in the most aggressive stage of the tumor (castration-resistant prostate cancer, CRPC) for which the standard treatment, docetaxel-based chemotherapy, can...
12.
Limonta P, Montagnani Marelli M, Mai S, Motta M, Martini L, Moretti R
Endocr Rev
. 2012 Jul;
33(5):784-811.
PMID: 22778172
The crucial role of pituitary GnRH receptors (GnRH-R) in the control of reproductive functions is well established. These receptors are the target of GnRH agonists (through receptor desensitization) and antagonists...
13.
Moretti R, Mai S, Montagnani Marelli M, Rizzi F, Bettuzzi S, Limonta P
Int J Oncol
. 2011 May;
39(1):225-34.
PMID: 21573492
The proapoptotic activity of nuclear clusterin (nCLU) in cancer cells is now well established. We previously showed that nCLU decreases the motility of prostate cancer cells by triggering a dramatic...
14.
Moretti R, Mai S, Montagnani Marelli M, Bani M, Ghilardi C, Giavazzi R, et al.
Endocrinology
. 2010 Aug;
151(10):4643-53.
PMID: 20685877
We showed previously that GnRH receptors are expressed in melanoma cells; their activation reduces cell growth and metastatic behavior. Here, we investigated whether GnRH agonists might affect the expression of...
15.
Montagnani Marelli M, Moretti R, Mai S, Muller O, Van Groeninghen J, Limonta P
Oncol Rep
. 2009 Apr;
21(5):1277-82.
PMID: 19360304
Malignant glioblastoma is one of the highest proliferative and invasive tumors within the central nervous system (CNS); the therapeutical options for this disease are still very poor. Receptors for gonadotropin-releasing...
16.
Montagnani Marelli M, Moretti R, Mai S, Januszkiewicz-Caulier J, Motta M, Limonta P
J Clin Endocrinol Metab
. 2009 Feb;
94(5):1761-7.
PMID: 19190109
Background: GnRH-II has been shown to exert a strong antiproliferative action on tumors of the female reproductive system. The data so far reported on the effects of GnRH-II on prostate...
17.
Moretti R, Montagnani Marelli M, Mai S, Limonta P
Int J Oncol
. 2008 Jul;
33(2):405-13.
PMID: 18636163
Cutaneous melanoma represents the leading cause of skin cancer deaths. The prognosis of highly aggressive, metastatic melanoma is still very poor, due to the resistance of the disseminated tumor to...
18.
Moretti R, Montagnani Marelli M, Mai S, Cariboni A, Scaltriti M, Bettuzzi S, et al.
Cancer Res
. 2007 Nov;
67(21):10325-33.
PMID: 17974975
Besides a fully processed, secreted form of clusterin (sCLU), an alternative proapoptotic form of the protein targeting the nucleus (nCLU) was recently described. The possible differential roles played by the...
19.
Montagnani Marelli M, Moretti R, Mai S, Procacci P, Limonta P
Int J Oncol
. 2006 Dec;
30(1):261-71.
PMID: 17143537
Androgen-independent prostate carcinoma is characterized by a high proliferation rate and by a strong metastatic behavior. We have previously shown that GnRH agonists exert a direct and specific inhibitory action...
20.
Montagnani Marelli M, Moretti R, Procacci P, Motta M, Limonta P
Int J Oncol
. 2006 Feb;
28(3):723-30.
PMID: 16465378
In its phase of androgen-independence, prostate carcinoma is characterized by a high proliferation rate and by a strong ability to give rise to metastases. IGF-I has been shown to exert...